Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration
2024-513042-12-01Phase 2Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2024
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised trial in perinatal arterial ischemic stroke (PAIS) comparing Darbepoetin arm with Placebo arm (2 arms). Primary endpoints: Change in stroke lesion size and brain growth and Differences in DTI parameters. Planned start Aug 2024; status: authorised.
02
Drugs
darbepoetin alfa
03
Conditions
perinatal arterial ischemic stroke (PAIS)
Beyond the preview
Go deeper on 2024-513042-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513042-12-01.